Inactive/Delisted stock
Aerovate Therapeutics Stock (NASDAQ:AVTE)
Previous Close
$2.68
52W Range
$2.63 - $884.98
50D Avg
$88.74
200D Avg
$82.18
Market Cap
$77.68M
Avg Vol (3M)
$7.99K
Beta
0.95
Div Yield
- (32.43%)
AVTE Company Profile
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.